There are an estimated 100,000 patients with polycythemia vera (PV) in the United States ([@A28]). Because there is no curative medical treatment option ([@A54]), these patients require disease management for the remainder of their lives. Patients with PV have an increased risk of mortality ([@A19]), often because of cardiovascular or thromboembolic events ([@A50]), and experience burdensome signs and symptoms ([@A13]; [@A50]). Advanced practitioners (APs), including nurse practitioners, PAs, and pharmacists, play key roles in managing these patients. Knowledge of current diagnostic criteria and management strategies is critical to prolonging survival and improving quality of life (QOL).

PATHOBIOLOGY AND DIAGNOSIS
==========================

Polycythemia vera is a myeloproliferative neoplasm (MPN) that is distinguished by erythrocytosis ([@A52]). Most patients with PV have activating mutations in *JAK2*, including *JAK2*V617F (95%--97%) and *JAK2* exon 12 mutations (2%--4%; [@A33]; [@A36]). Under normal conditions, JAK2 is a key regulator of hematopoiesis ([@A39]); however, constitutive activation is associated with PV disease features, including excessive hematopoiesis and splenomegaly ([@A39]).

**Case Study Continued**

Mr. M was diagnosed with PV per the 2008 World Health Organization (WHO) guidelines ([Table 1](#T1){ref-type="fig"}; [@A51]; [@A52]). He presented with the two major criteria (i.e., erythrocytosis and the *JAK2*V617F mutation) and one minor criterion (i.e., low or lower end of normal serum erythropoietin levels).
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Although the WHO guidelines are the standard for diagnosing PV, they may not aid in identifying patients with masked PV, a condition characterized by *JAK2* mutations and PV-consistent bone marrow morphology, despite subthreshold hemoglobin levels ([@A5]). Consequently, the 2016 WHO guidelines include lower thresholds for hemoglobin levels and inclusion of bone marrow results in the major criteria ([Table 1](#T1){ref-type="fig"}).

NATURAL HISTORY AND DISEASE BURDEN
==================================

Mr. M presented with fatigue, headaches, pruritus, and difficulty sleeping. Patients with PV may also present with a thromboembolic event or other disease-related signs, including a palpable spleen ([@A50]). However, many patients are diagnosed asymptomatically based on routine blood work ([@A35]). Iron deficiency may result from the expanding erythrocyte population with a lower-than-normal erythropoietin level, and may mask the diagnosis of PV ([@A21]). As the disease progresses, patients are at risk for cardiovascular, thromboembolic, and hemorrhagic events and may develop solid malignancies ([@A26]; [@A50]). Polycythemia vera may also transform to myelofibrosis (MF), which is diagnosed by 2008 International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria ([Table 2](#T2){ref-type="fig"}; [@A10]), and/or transform to acute myeloid leukemia (AML), which is identifiable by ≥ 20% blasts in the peripheral blood or bone marrow as well as by extramedullary tumoral blast proliferation (myeloid sarcoma) per 2008 WHO criteria ([@A56]). Cardiovascular or thromboembolic events, solid malignancies, and disease transformation to MF or AML are the leading contributors to an increased mortality risk for patients with PV compared with the age- and sex-matched general population ([@A19]; [@A26]; [@A50]). Splenomegaly-associated symptoms, including early satiety, and abdominal discomfort are not uncommon in patients with PV ([@A13]). Based on patient-reported experiences, PV-related symptoms reduce QOL and may hinder activities of daily living and work productivity ([@A29]).
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MANAGEMENT
==========

**Treatment Goals**

The treatment goals for PV are to reduce thromboembolic and hemorrhagic risk, to manage disease-related symptoms, and to minimize the risk of fibrotic or leukemic transformation ([@A4]). Patients with a history of thromboembolic events and those aged ≥ 60 years have increased thrombotic risk ([@A5]; [@A54]). In addition, the Cytoreductive Therapy in PV (CYTOPV) trial demonstrated the importance of controlling hematocrit and possibly WBC count. Maintaining a hematocrit \< 45% was associated with a fourfold reduced risk of death from cardiovascular or thrombotic events compared with hematocrit maintenance between 45% and 55% ([@A27]). Similarly, WBC count \< 7 × 10^9^/L was associated with a fourfold reduced risk of major thrombosis compared with ≥ 11 × 10^9^/L ([@A6]). In our case, the patient presented at 65 years of age with a hematocrit of 54%, indicating high risk for thromboembolic events.

It is important that APs develop an evidence-based treatment plan ([Figure 1](#F1){ref-type="fig"}). Patients should be monitored routinely for changes in hematocrit and blood count ([@A4]), with the frequency dictated by the patient's disease severity and risk of complications and/or progression. Those with stable blood count may require follow-up every 3 months, whereas some patients, including those with a recent diagnosis or change in treatment, may require weekly monitoring to achieve hematocrit control and appropriate dosing of cytoreductive therapy. Symptom burden should be regularly assessed with an objective instrument such as the MPN Symptom Assessment Form ([Figure 2](#F2){ref-type="fig"}; [@A4]; [@A44]). Finally, it is important to address comorbidities and history of cardiovascular, thromboembolic, and hemorrhagic events. An emphasis should be placed on achieving optimal control of conventional cardiovascular risk factors (i.e., elevated cholesterol, current smoking status, diabetes mellitus, and high systolic blood pressure; [@A17]) and monitoring for signs of disease transformation to MF ([Table 2](#T2){ref-type="fig"}) ([@A10]) or AML ([@A56]).
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**Case Study Continued**

Following diagnosis, Mr. M received weekly phlebotomies until hematocrit was \< 45% and started low-dose aspirin (81 mg/d), as is recommended for patients with PV ([@A24]; [@A27]) unless specific contraindications to low-dose aspirin exist, such as extreme thrombocytosis (platelet count \> 1,000 × 10^9^/L), at which point acquired von Willebrand syndrome should be ruled out due to risk of bleeding ([@A49]). Because his age was \> 60 years, the patient was considered high risk for thrombosis, and therefore started cytoreductive therapy with hydroxyurea.

**Traditional Treatment Options**

Best practices should be used for phlebotomy, including temporary cessation of the phlebotomy or administration of intravenous fluids for hypotension or other phlebotomy-related symptoms (e.g., acute illness, dizziness, dehydration; [@A34]). Patients who are high risk (≥ 60 years or with a history of thromboembolic events) should be started on cytoreductive therapy. Additionally, patients with poor disease control with aspirin and phlebotomy alone (continually elevated blood count and/or persistent signs or symptoms) may benefit from the addition of cytoreductive treatment ([@A4]) with hydroxyurea ([@A16]; [@A22]) or interferon-α ([@A18]).

Hydroxyurea is often recommended for first-line cytoreductive therapy ([@A54]); however, approximately 1 in 4 patients become resistant or intolerant ([@A1]) per European LeukemiaNet (ELN) criteria ([Table 3](#T3){ref-type="fig"}). Hydroxyurea resistance is associated with a 5.6-fold increased risk of death compared with hydroxyurea responders ([@A1]). Approaches to the treatment of PV---including indications, common adverse events, and clinical implications---are provided in [Table 4](#T4){ref-type="fig"}.

![European LeukemiaNet Criteria for Resistance to or Intolerance of Hydroxyurea in Patients With Polycythemia Vera](jadp-09-056-g05){#T3}

![Approaches to the Treatment of Polycythemia Vera With Clinical Implications](jadp-09-056-g06){#T4}

**Case Study Continued**

Mr. M's disease was successfully managed for a few years. In regular follow-up, the WBC count increased over the course of a year to 20 × 10^9^/L, and the patient developed progressive fatigue, pruritus, and night sweats, despite administering hydroxyurea at the maximum tolerated dose, indicating hydroxyurea resistance.

**Treatment Options for Patients With PV Resistant to or Intolerant of Hydroxyurea**

Ruxolitinib (Jakafi \[US\] or Jakavi \[non-US\]) is the only agent approved by the US Food and Drug Administration (FDA) for patients with PV who have had an inadequate response to or are intolerant of hydroxyurea ([@A20]) and by the European Medicines Agency (EMA) for adult patients with PV who are resistant to or intolerant of hydroxyurea ([@A14]). Although interferon-α is an effective treatment option for some patients, it is not indicated by the FDA or EMA for patients with PV. Long-term treatment with interferon-α may be challenging for some patients because of its inconvenience as an injectable medication and treatment-related adverse events, which may include chills, depression, diarrhea, fatigue, fever, headache, musculoskeletal pain, myalgia, nausea, and weight loss ([@A18]). For these reasons, we did not consider interferon-α for Mr. M.

Regulatory approval of the oral JAK1/JAK2 inhibitor ruxolitinib ([@A41]) was based on the randomized, open-label, multicenter phase III RESPONSE trial, which evaluated ruxolitinib vs. best available therapy (BAT; i.e., hydroxyurea, interferon-α, anagrelide, immunomodulators, pipobroman, and observation alone) in patients with PV who required phlebotomy to control hematocrit, had splenomegaly, and were resistant to or intolerant of hydroxyurea ([@A55]). Ruxolitinib was superior to BAT for hematocrit control without phlebotomy, reduction in enlarged spleen size, and normalization of blood count ([@A55]). In addition, treatment with ruxolitinib may reduce the severity of PV-related symptoms and improve QOL based on patient-reported outcomes ([@A30]; [@A55]).

Adverse events with ruxolitinib were primarily grade 1 or 2, with a lower grade 3 or 4 adverse event rate (28.8 per 100 patient-years of exposure) compared with BAT (44.0 per 100 patient-years of exposure; [@A55]). Among patients treated with ruxolitinib, MF and AML transformation rates were consistent with published rates for high-risk patients with PV ([@A15]; [@A37]; [@A55]). Herpes zoster infections were all grade 1 or 2 and only occurred with ruxolitinib (6.4%); no patients discontinued ruxolitinib because of herpes zoster ([@A55]). Nonmelanoma skin cancer occurred in more patients in the ruxolitinib arm (3.6%) compared with the BAT arm (1.8%); however, all patients in the ruxolitinib arm had a history of nonmelanoma skin cancer or precancerous lesions ([@A55]). No patients died while receiving randomized treatment; two patients died for reasons that were considered unrelated to ruxolitinib treatment after crossing over to ruxolitinib from BAT.

**Case Study Continued**

Because of hydroxyurea resistance, Mr. M was evaluated for treatment with ruxolitinib. Hepatic, renal, and platelet function were noted to be within normal limits. Review of the medication profile did not reveal any potential drug-drug interactions. Therefore, he was started on ruxolitinib 10 mg twice daily. After 3 months of treatment, Mr. M maintained hematocrit control and had improvements in symptoms and leukocytosis.

Ruxolitinib exposure may be affected by hepatic and renal impairment ([@A12]), as well as concomitant treatment with a cytochrome P450 3A4 inhibitor ([@A45]), and dosing should be modified as appropriate ([@A20]). Mr. M was informed about the risks for herpes zoster infections and nonmelanoma skin cancer and continues to be monitored accordingly.

ASPECTS OF INDIVIDUALIZED PATIENT MANAGEMENT
============================================

Advanced practitioners play a critical role in managing patients with PV. Regular patient contact enables the AP to closely monitor laboratory values to optimize medical management and to educate patients about potential disease symptoms, adverse events related to current and/or alternative treatment options, and lifestyle or treatment modifications to achieve improvements ([@A42]). When dispensing medication, pharmacists are provided an opportunity to inform patients about the specifics of treatment delivery and dosing as well as potential drug-drug interactions for those patients receiving concomitant medications. Finally, APs can facilitate improved patient compliance and adherence by placing reminder phone calls to patients, offering direct-to-patient deliveries, and coordinating with health plans and patient assistance programs to facilitate payment.

DISCUSSION
==========

Patients with PV require long-term management to prolong survival and improve QOL. Familiarity with the 2008 WHO diagnostic criteria ([@A52]), as well as possible exceptions for masked PV ([@A5]), will allow the AP to quickly and accurately identify patients with PV. Although nearly all patients should initially receive treatment with aspirin ([@A24]) and phlebotomy to achieve a target hematocrit \< 45% ([@A4]; [@A27]), management should evolve with the natural course of the disease ([@A4]). Management decisions should be informed by current evidence, based on both objective measures (e.g., CBC, bone marrow biopsy, manual spleen palpation) and subjective measures (e.g., patient-reported symptoms with comprehensive instruments such as the Myeloproliferative Neoplasm Symptom Assessment Form) to identify patients who will benefit from the addition of cytoreductive treatment such as hydroxyurea ([@A4]; [@A44]). Knowledge of the ELN criteria for hydroxyurea resistance and intolerance ([@A8]) will allow the AP in hematology/oncology to identify high-risk patients who may benefit from a change in therapy, including consideration of ruxolitinib ([@A55]). Advanced practitioners may also identify high-risk patients in need of an alternate disease management strategy based on the IWG-MRT criteria for fibrotic transformation ([@A10]) and the WHO criteria for leukemic transformation ([@A56]). Early diagnosis and evidence-based patient management by APs will promote improved outcomes and better QOL.
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